Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-27
2006-06-27
Russel, Jeffrey E. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S186100, C424S211100, C530S324000
Reexamination Certificate
active
07067487
ABSTRACT:
The invention relates to peptides derived from or similar to the Emsprotein of pestiviruses for type-specific diagnosis of infection, for eliciting antibiotic activity, and for transport of substances into a cell. For these purposes, the invention provides, among other things, an isolated, synthetic or recombinant protein or peptide module or functional equivalent thereof comprising an amino acid sequence having significant homology to, for example, an amino acid sequence of a peptide located from about amino acid position (a) 194 to about 220 in a pestiviral Emsprotein (b) 59 to about 88 in an L3 loop of a cytotoxic RNase of a ribosome-inactivating protein, or (c) 187 to about 223 in a respiratory syncytial virus G-protein.
REFERENCES:
patent: 5877153 (1999-03-01), Harris et al.
patent: 6149911 (2000-11-01), Binz et al.
patent: 6200955 (2001-03-01), Harris et al.
patent: 6261569 (2001-07-01), Comis et al.
patent: 2005/0027457 (2005-02-01), Mandell et al.
patent: 0 982 401 (2000-03-01), None
patent: 0 982 402 (2000-03-01), None
patent: WO 95/27787 (1995-10-01), None
patent: WO 95/34308 (1995-12-01), None
patent: WO 97/47312 (1997-12-01), None
patent: WO 97/47312 (1997-12-01), None
patent: WO 97/49726 (1997-12-01), None
patent: WO 97/49726 (1997-12-01), None
patent: WO 99/03987 (1999-01-01), None
patent: WO 99/03987 (1999-01-01), None
patent: WO 99/06569 (1999-02-01), None
patent: WO 00/09701 (2000-02-01), None
patent: WO 02/00882 (2002-01-01), None
patent: WO 02/00882 (2002-01-01), None
Langedijk et al. Enzyme-Linked Immunosorbent Assay Using a Virus . . . Journal Of Clinical Microbiology. Mar. 2001, vol. 39, No. 3, pp. 906-912.
International Search Report, International Application No. PCT/NL01/00484, dated Mar. 22, 2002 (7 pages).
International Preliminary Examination Report, International Application No. PCT/NL01/00484, dated Jul. 9, 2002 (3 pages).
Feldman, Steven A., et al., “Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G,” 73(8) Journal of Virology 6610-17 (Aug. 1999).
Guichard, Gilles, et al., “Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics,” 91 Proc. Natl. Acad. Sci. USA 9765-69 (Oct. 1994).
Kishore, Ram, et al., “Interaction of the NH2-terminal Domain of Fibronectin with Heparin,” 272(27) The Journal of Biological Chemistry 17078-85 (1997).
Mancheno, Jose M., et al., “Predictive Study of the Conformation of the Cytotoxic Protein α-Sarcin: A Structural Model to Explain α-Sarcin-Membrane Interaction,” 172 J. Theor. Biol. 259-67 (1995).
Mayo, Kevin H., “Recent advances in the design and construction of synthetic peptides: for the love of basics or just for the technology of it,” 18 Tibtech 212-17 (May 2000).
Moormann, R.J.M, “Recent Developments in Pig Vaccinology,” Proceedings of the 14th IPVS Congress, Gologna, Italy, 25-29 (Jul. 7-10, 1996).
Yang, Xiaojing, et al., “Insights into specificity of cleavage and mechanism of cell entry from the crystal structure of the highly specific Aspergillus ribotoxin, restrictocin,” 4(7) Structure 837-52 (1996).
PCT International Search Report, PCT/NL01/00484, dated Mar. 22. 2002.
Chang et al., HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region, AIDS, 1997, pp. 1421-1431, vol. 11, No. 12.
Lindgren et al., Cell-penetrating peptides, Review, Mar. 2000, pp. 99-103, vol. 21.
Pepscan Systems B.V.
Russel Jeffrey E.
TraskBritt
LandOfFree
Transport peptides such as C-terminal E rns peptide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transport peptides such as C-terminal E rns peptide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transport peptides such as C-terminal E rns peptide and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696782